Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Abstract: Disclosed is a method of treating a fine line or wrinkle in a person's skin. The method includes topically applying to the fine line or wrinkle a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin. Topical application of the composition to the fine line or wrinkle reduces the appearance of the fine line or wrinkle.

Abstract: A hair care composition having from about 10% to about 25% of one or more surfactants; from about 0.01% to 10% of one or more particulate scalp health agents; from about 0.01% to 10% of one or more surfactant soluble scalp health agents; from about 0.01% to 5% of one or more cationic polymers selected from the group consisting of a cationic cellulose; from about 0.01% to 5% of one or more cationic polymers selected from group consisting of one or more cationic guar polymers; and wherein an on-scalp deposition of the particulate scalp health agent deposition efficiency is increased by about 50% compared to a control with no soluble scalp health agent.

Abstract: A foamable skin composition comprises, in % by weight of the foamable skin composition, at least one C12-C22 fatty acid at a concentration of 1-3%, at least one C12-C22 fatty alcohol at a concentration of 1-5%, at least one ester and/or vegetable oil at a concentration of 1-40%, at least one non-ionic surfactant at a concentration of 1-15%, at least one emollient at a concentration of 0.5-10% and water. The foamable skin composition has an acidic pH but still forms a stable form following dispensing.

Abstract: The invention relates to a composition which contains at least one anionic surfactant, a betaine surfactant, a mixture of N-methyl-N-acylglucamines, the acyl groups of which correspond to those of natural coconut oil and/or palm kernel oil, a glycerol derivative, a solvent and optionally one or more additives. The invention also relates to a method for producing the composition. The invention further relates to the use of the composition for the treatment or care of skin or hair, for example as a shampoo, face cleaner, liquid cleaner or shower gel.

Abstract: A transdermal patch is provided for use during oil delivery to a user's skin. The patch has a first foam member and a second foam member positioned adjacent the first foam member. An adhesive member is attached to the second foam member for securing the patch to a user's skin. A release liner covers and extends across the adhesive member. A gap can be formed between the first foam member and the second foam member and surrounds the first foam member. The first foam member has a thickness which is greater than a thickness of the second foam member.

Abstract: Disclosed is a method for preparing cross-linked hyaluronic acid-based cell scaffold material. The hyaluronic acid-based cell scaffold is obtained by subjecting a hyaluronic acid and a disulfide cross-linking agent to an amidation reaction, followed by dialysis-freeze drying. The cell scaffold has abundant pores, good mechanical strength which ensures that the scaffold does not rupture in transplantation, and good biocompatibility. The method is advantageous in that the raw material is easy to obtain, the reaction condition is moderate, and the process is simple. Cross-linked networks of the prepared hydrogel contain disulfide bonds, which can quickly split into single chains at the presence of small molecular glutathione. The hyaluronic acid-based cell scaffold has flexibly controllable mechanical property, disaggregation ability, and swelling property, and therefore has wide applications in facilitating cartilage injury repair, skin repair, cell culture, etc.

Abstract: Methods, systems, and devices are disclosed for fabricating and implementing nanoscale and microscale structured carriers to provide guided, targeted, and on-demand delivery of molecules and biochemical substances for a variety of applications including diagnosis and/or treatment (theranostics) of diseases in humans and animals. In some aspects, a nanostructure carrier can be synthesized in the form of a nanobowl, which may include an actuatable capping particle that can be opened (and in some implementations, closed) on demand. In some aspects, a nanostructure carrier can be synthesized in the form of a hollow porous nanoparticle with a functionalized interior and/or exterior to attach payload substances and substances for magnetically guided delivery and controlled release of substance payloads.

Abstract: Compositions and methods for efficient delivery of therapeutic agents in vivo are provided. Typically, the compositions are in the form of polymeric particles formed from one or more therapeutic agent complexed with a polycationic polymer which is further encapsulated in one or more amphiphilic polymers, preferably diblock copolymer of a polyalkylene oxide and a polyester such as poly(D,L-lactide)-poly(ethylene glycol) (PLA-PEG). In the preferred embodiments, the chemotherapeutic agent reduces, or inhibits N-glycosylation of one or more receptor tyrosine kinases of cancer cells. Methods of using the particles to treat cancer are also provided.

Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.

Abstract: Composition comprising avermectin compounds without solid fatty substances The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one active phase comprising at least one active compound chosen from avermectin compounds and at least one solvent and/or propenetrating agent of avermectin compounds, where the composition comprises less than 3% by weight of solid fatty substances at room temperature and at atmospheric pressure, relative to the total weight of the composition. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and a least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: An edible orally disintegrating tablet dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible orally disintegrating tablet dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.

Abstract: The purpose of the present invention is to solve the problem, in powder hair dye compositions that contain a percarbonate, that a change occurs in the dyed color tone before and after storage when the composition contains metaaminophenol, 5-aminoorthocresol, resorcin, or a salt thereof, as an oxidation dye. To solve the aforementioned problem, a powder hair dye composition containing (A) a percarbonate, (B) a starch, and (C) an oxidation dye is provided, characterized in that the composition contains at least 7 mass % starch (B) and in that the oxidation dye (C) contains at least one selected from metaaminophenol, 5-aminoorthocresol, resorcin, and salts thereof. Thus, a powder hair dye composition can be obtained which suppresses change in the dye color tone before and after storage and which has excellent storage stability.

Abstract: Hair treatment agents containing a mixture of special linear alkanes, an amidoamine and/or a cationized amidoamine, and at least one cationic surfactant (esterquat and/or quaternary ammonium compound) are provided. In one example, the hair treatment agents are suitable for the care of hair, in particular to improve the wet and dry combability, the disentanglement, the hold, and the gloss of hair.

Abstract: Embodiments enables a wearable phototherapy apparatus that produces beneficial effects to a human body such as activation of stem cells, improvement in strength, improvement in stamina, pain relief via a non-transdermal container. May include an optional transdermal container that releases or increases copper peptide GHK-Cu in a subject's body. The non-transdermal apparatus reflects or emits specific wavelengths of light to elevate levels of the copper peptide GHK-Cu in the body. The non-transdermal apparatus includes one or more materials that prevent the Left-Handed molecule from direct contact with the body while the enclosure is coupled to the body and prevents the Left-Handed molecules from entering the body.

Abstract: The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.

Abstract: An adhesive preparation containing bisoprolol includes a backing and a pressure-sensitive adhesive layer formed on one side of the backing. The pressure-sensitive adhesive layer contains a polymer prepared through copolymerization of monomer components including a hydroxyl group-containing monomer and an alkyl (meth)acrylate monomer (component (A)), a polymer prepared through copolymerization of monomer components including a methyl methacrylate monomer and a butyl methacrylate monomer (component (B)), and bisoprolol (component (C)).

Abstract: Provided is a gel composition including a partial degradation product of the galactose moiety of galactoxyloglucan, a compound that is a mixture of one kind or two or more kinds selected from magnesium salt, calcium salt, aluminum salt, and sodium salt, and an aqueous solvent.

Abstract: The present invention provides compositions and methods of using the compositions as personal care products and other consumer and industrial products, wherein the compositions comprise bio-based farnesene and/or compounds derived from the bio-based farnesene.